IDEAYA Biosciences, Inc. cotiza a 34.26 USD y tiene una capitalización bursátil de $3.3B. En los últimos 12 meses ha facturado $234M con un margen de flujo de caja libre del -33.6%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
IDEAYA Biosciences, Inc., a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company offers Darovasertib, an oral, potent, and selective protein kinase, C (PKC) inhibitor for the treatment of uveal melanoma, ocular…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-02 |
|---|---|---|---|---|
| Real | — | $-1.22 | $-1.11 | $-0.94 |
| Estimado | $-1.16 | $-1.05 | $-0.98 | $-0.95 |
| Sorpresa | — | -16.2% | -13.3% | +1.1% |
| Métrica | IDYA | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | -72.8% | -38.6% | -34.2% |
| Net Margin | -52.0% | -33.6% | -18.4% |
| FCF Margin | -33.6% | -13.9% | -19.7% |
| ROE | -11.1% | -40.4% | +29.3% |
| ROA | -10.3% | -32.0% | +21.8% |
| Current Ratio | 11.34 | 2.84 | +8.50 |
| Debt / Equity | — | 0.28 | — |